BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

Annals of Hematology
Carlos SantamaríaMarcos González

Abstract

We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.

References

Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·S M TannerA de La Chapelle
May 29, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·M Carmen ChillónJesús F San Miguel
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marianne BienzThomas Pabst
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia D BaldusGerhard Ehninger
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciUNKNOWN Cancer and Leukemia Group B Study
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaClara D Bloomfield
Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg

❮ Previous
Next ❯

Citations

Apr 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ann-Kathrin EisfeldAlbert de la Chapelle
Nov 19, 2011·Hematology/oncology Clinics of North America·Chezi Ganzel, Jacob M Rowe
Nov 11, 2011·American Journal of Hematology·Hady GhanemImad A Tabbara
Aug 19, 2014·British Journal of Haematology·Anne S RougPeter Hokland
Mar 19, 2013·Experimental Hematology & Oncology·Jaap BrandErik H van Beers
Dec 27, 2011·Biochemical and Biophysical Research Communications·Alessandra FranzoniGiuseppe Damante
Sep 15, 2016·Science Signaling·Laure DavidJean-Sébastien Hoffmann
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
May 17, 2017·Expert Opinion on Emerging Drugs·Abdallah Abou Zahr, Gautam Borthakur
Aug 8, 2018·Expert Opinion on Investigational Drugs·Kamal Chamoun, Gautam Borthakur
Jun 16, 2010·European Journal of Haematology·Mauri HämäläinenVeli Kairisto
Feb 6, 2018·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Adel A HagagAmal Ezzat Abd El-Lateef
Nov 27, 2020·International Journal of Laboratory Hematology·Irena MarjanovicNatasa Tosic
Oct 27, 2020·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Nevine F ShafikNaglaa M Hassan
May 11, 2021·Frontiers in Oncology·Madeleine BirgerssonKathryn A Skelding

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.